ExploreCME: Diving deep into PANCE Prep!

Diabetes, Decoded

Subscriber Episode • • Phillip

Share episode

This episode is only available to subscribers.

ExploreCME: Diving deep into PANCE Prep! +

Get access to our entire back catalogue
SPEAKER_01:

Welcome back to the deep dive, where we take high stakes, high yield information, and distill it down into the core knowledge you need.

SPEAKER_00:

Today we are strapping in for a structured, comprehensive deep dive into diabetes molitis.

SPEAKER_01:

That's right. Type 1, type 2, and all the high yield corners in between.

SPEAKER_00:

And we've organized this discussion not just as, you know, a list of facts, but really around the entire patient journey.

SPEAKER_01:

Following those clinical task areas you have to master from pathophysiology and diagnosis all the way to long-term management.

SPEAKER_00:

Exactly. The mission is delivering a crisp, medical school level review, connecting the dots.

SPEAKER_01:

Aaron Powell We want to link the molecular failures directly to your clinical decision making. Okay, let's unpack this.

SPEAKER_00:

Aaron Powell So we have to start with the foundational science. Right.

SPEAKER_01:

The fundamental concepts.

SPEAKER_00:

We have to clearly differentiate the root causes. Type 1 diabetes, or a T1DM, is uh it's fundamentally an autoimmune disorder.

SPEAKER_01:

Aaron Powell So the body is attacking itself.

SPEAKER_00:

Precisely. We're talking about the complete targeted destruction of the pancreatic beta cells.

SPEAKER_01:

And that's irreversible.

SPEAKER_00:

Aaron Powell It is. It leads to an absolute deficiency of insulin. It's a catabolic state. Insulin is gone, glucagon is unopposed, and the body just can't use glucose.

SPEAKER_01:

Aaron Powell, so it starts burning fat and muscle instead.

SPEAKER_00:

It has to. And what's fascinating is something you pointed out is that T1DM doesn't just happen overnight.

SPEAKER_01:

Right. It's not like flipping a switch. The sources say it's actually a slow burn.

SPEAKER_00:

It's a stage progression. It can take years.

SPEAKER_01:

And we only see the final stage.

SPEAKER_00:

Usually. The process begins very subtly at stage one, where you have those telltale autoantibodies like GAD65 or IAA.

SPEAKER_01:

But the patient is completely normoglycemic. They feel fine.

SPEAKER_00:

Totally fine. It only progresses to stage three when the symptoms hit, often with that classic sudden onset.

SPEAKER_01:

And there's a genetic link there, right, with HLA haplotypes.

SPEAKER_00:

Yes. Certain HLA haplotypes predispose you, and then an environmental trigger like a viral infection is a prime suspect is thought to kick off that autoimmune injury.

SPEAKER_01:

So T1 DM is a sudden onset of symptoms from an absolute lack of insulin. When we pivot to type 2, T2DM, the story is completely different.

SPEAKER_00:

Aaron Ross Powell Entirely. We're shifting from autoimmune destruction to um metabolic overload.

SPEAKER_01:

And the key driver there is insulin resistance.

SPEAKER_00:

Precisely. That resistance starts primarily in peripheral tissues, muscle, and liver, and it's so strongly linked to visceral obesity.

SPEAKER_01:

The fat around the organs?

SPEAKER_00:

Yes. That central adiposity creates this uh inflammatory state that directly messes with the body's ability to respond to insulin signaling.

SPEAKER_01:

So if resistance is the first problem, what's the pancreas doing? Does it just give up?

SPEAKER_00:

Initially, no, not at all. It tries to compensate. It works overtime, just cranking out huge amounts of insulin.

SPEAKER_01:

Which is why you see hyperinsulinemia and high C peptide levels early on.

SPEAKER_00:

Exactly. But it's a progressive failure. Over time, those beta cells get exhausted. We start seeing amyloid protein depositing in the eyelids.

SPEAKER_01:

And that leads to their ultimate dysfunction.

SPEAKER_00:

And then you get a relative insulin deficiency. So T2DM is really a two-pronged problem. The resistance plus the eventual failure to keep up production.

SPEAKER_01:

Okay, before we move on, we have to touch on the mimics. LADA and MODY. What are the key distinctions there?

SPEAKER_00:

Aaron Ross Powell LADA, latent autoimmune diabetes of adults, is essentially type one.

SPEAKER_01:

But it's slow.

SPEAKER_00:

Aaron Powell It's very slow and it presents in adulthood. It gets misdiagnosed as type two all the time.

SPEAKER_01:

Until they need insulin really quickly, or you check the labs.

SPEAKER_00:

Right. You check for those GAD65 antibodies and they'll be positive. MODY is uh completely different. It's a single gene defect.

SPEAKER_01:

So it runs in families.

SPEAKER_00:

Autosomal dominant. And the key clinical clue is that these patients are typically non-obese, and the onset is before age 25.

SPEAKER_01:

And we can't forget secondary causes. A patient starts a new medication.

SPEAKER_00:

And suddenly their glucose is high. Yeah. You have to think about high-dose glucocorticoids, atypical antipsychotics, or even something like Cushing syndrome.

SPEAKER_01:

Okay, so we understand the engine failure. Now how do we spot it? Let's talk clinical presentation, the history and physical exam.

SPEAKER_00:

And the history for T1DM versus T2DM is, like you said, fire and ice. It's a total contrast.

SPEAKER_01:

T1 DM is abrupt.

SPEAKER_00:

It is. Often a crisis. You get the classic 3PS polyuria, polydipsia, polyphagia with rapid unexplained weight loss.

SPEAKER_01:

And since insulin is totally absent, they can't suppress ketogenesis.

SPEAKER_00:

Right. Which means DKA diabetic ketoacidosis is often the very first sign.

SPEAKER_01:

Aaron Ross Powell Whereas T2DM is so much more subtle, you almost have to hunt for it.

SPEAKER_00:

Insidious is the word. It's often asymptomatic for years.

SPEAKER_01:

So patients only show up when a complication appears.

SPEAKER_00:

Exactly. Like blurred vision from early retinopathy or those recurrent frustrating infections.

SPEAKER_01:

Candital infections like vulvivaginitis.

SPEAKER_00:

A classic one.

SPEAKER_01:

So if the T2DM history is subtle, what physical exam findings scream insulin resistance at you?

SPEAKER_00:

The single most high yield finding is a canthesis nigricans.

SPEAKER_01:

That velvety, dark hyperpigmentation.

SPEAKER_00:

Usually in the axilla, the neck, or the groin. That's a direct sign of hyperinsulinemia.

SPEAKER_01:

And beyond that, the exam is really about looking for chronic damage.

SPEAKER_00:

It is. You have to assess the extremities, looking for signs of peripheral neuropathy.

SPEAKER_01:

That classic stocking glove sensory loss pattern.

SPEAKER_00:

Right. And you need to do objective tests. You check for absent ankle jerks. That reflex is one of the first things to go.

SPEAKER_01:

And most critically.

SPEAKER_00:

The annual foot exam with the 5.07 Semizweinstein monofilament.

SPEAKER_01:

Because loss of that protective sensation is a huge red flag for future ulcers.

SPEAKER_00:

A massive red flag. And you're also looking for those really dramatic foot deformities.

SPEAKER_01:

Like clottes or the rocker bottom foot.

SPEAKER_00:

Yes, that rocker bottom appearance is indicative of sharkoarthropathy. It's a destructive joint process from severe neglected neuropathy. It's it's truly terrifying to see.

SPEAKER_01:

So let's move on to the labs. Using diagnostic and laboratory studies, this is where we make it official.

SPEAKER_00:

Right. For diabetes mellitus, you need one of four tests to be positive.

SPEAKER_01:

And confirmed on a separate day.

SPEAKER_00:

Confirmed on a separate day, unless the patient is acutely symptomatic with just sky-high glucose.

SPEAKER_01:

Okay, hit us with those four numbers we can't forget.

SPEAKER_00:

First, fasting plasma glucose, or FPG, of a 126 or higher. Second. Hemoglobin A1T of 6.5% or higher. Third, a two-hour oral glucose tolerance test result of 200 or higher.

SPEAKER_01:

And the last one for symptomatic patients.

SPEAKER_00:

A random glucose of 200 or higher, plus those classic symptoms, gets you the diagnosis right away.

SPEAKER_01:

And we have to mention prediabetes. An A1C between 5.7% and 6.4%.

SPEAKER_00:

Or a fasting glucose of 100 to 125. Those are the warning signs. That's where we have to intervene aggressively.

SPEAKER_01:

Absolutely. So once you've confirmed diabetes in an adult, how do you differentiate, especially if you suspect LADA? You can't just rely on A1C alone.

SPEAKER_00:

We're absolutely right. You need to establish the pathology.

SPEAKER_01:

Yeah.

SPEAKER_00:

And that's where the differentiation tests come in.

SPEAKER_01:

Yeah, autoantibodies.

SPEAKER_00:

Primarily, yes. We look for GAD65, IA2, ZNT8. A positive test confirms T1DM or LADA. The other powerful tool is C peptide.

SPEAKER_01:

Right. Explain C peptide. Why is that a better measure than just checking an insulin level?

SPEAKER_00:

It's a great question. When the pancreas makes insulin, it cleaves off C peptide. It's secreted in a one-to-one ratio with insulin, but the liver doesn't clear it. Exactly. The liver doesn't extract it, so it's a much more stable, reliable proxy for how much insulin your own body is making.

SPEAKER_01:

So in long-standing type one, it'll be low or absent.

SPEAKER_00:

Total beta cell failure.

SPEAKER_01:

But in early type two?

SPEAKER_00:

It'll be normal or even elevated because the pancreas is still trying to overcome that resistance. It's a key test for planning treatment.

SPEAKER_01:

All right, we've diagnosed the patient. We understand the mechanism. Now, pharmaceutical therapeutics. The toolkit.

SPEAKER_00:

Here's where it gets really interesting.

SPEAKER_01:

Let's start with insulin. The bedrock for type one and advanced type two.

SPEAKER_00:

Insulin management is all about understanding pharmacokinetics.

SPEAKER_01:

The action profiles.

SPEAKER_00:

Exactly. For meals, you need rapid coverage. So you use rapid-acting insulins like Lispro or Aspart. They kick in within five to fifteen minutes.

SPEAKER_01:

Mimicking a natural insulin release.

SPEAKER_00:

Yes. And then you need your basal coverage, your background insulin.

SPEAKER_01:

The long-acting ones like Largine or Degludec, how do they provide such a flat long duration?

SPEAKER_00:

Aaron Powell It's really sophisticated chemistry. When you inject them subcutaneously, they form these um molecular clumps.

SPEAKER_01:

Aaron Powell So they don't just float around in the blood?

SPEAKER_00:

No, they form multihexamers or microprecipitates under the skin. Think of it like a microdepositive insulin that releases slowly and reliably over a full 24 hours.

SPEAKER_01:

Aaron Powell What about short-acting or regular insulin? Where does that fit in?

SPEAKER_00:

Regular insulin is really for high acuity situations.

SPEAKER_01:

Like DKA.

SPEAKER_00:

Precisely. Its key feature is that you can give it intravenously, which makes it the standard of care for emergencies or in the ICU.

SPEAKER_01:

And of course, with any insulin, we have to counsel on the side effects.

SPEAKER_00:

Unavoidable. Hypoglycemia, weight gain, and lipohypertrophy if you don't rotate injection sites.

SPEAKER_01:

Okay, let's switch to T2DM, where we have this arsenal of non-insulin agents. What is the undisputed first-line therapy?

SPEAKER_00:

Metformin. A big one-eyed. It's still the king.

SPEAKER_01:

Why? Why does it still hold that crown?

SPEAKER_00:

Because of its efficacy, low cost, and importantly, its low risk of hypoglycemia. Its main mechanism is it primarily decreases patic glucose production. It just tells the liver to stop dumping so much sugar into the bloodstream.

SPEAKER_01:

But it has that one major contraindication we always have to remember.

SPEAKER_00:

Absolutely. The rare but very serious risk of lactic acidosis. So it is absolutely contraindicated if the patient's EGFR drops below 30.

SPEAKER_01:

We also watch for B12 deficiency.

SPEAKER_00:

With long-term use, yes.

SPEAKER_01:

Now for the game changers. The drugs with massive cardiovascular and renal benefits.

SPEAKER_00:

You're talking about the SGLT2 inhibitors, the flu sentens.

SPEAKER_01:

They completely changed our management approach.

SPEAKER_00:

They did. Their mechanism is fascinating. They block glucose reabsorption in the proximal renal tubule.

SPEAKER_01:

So you just pee out the excess sugar.

SPEAKER_00:

You literally spill glucose and some water and sodium out into the urine. And the benefits go way beyond just glucose lowering.

SPEAKER_01:

Right. They reduce heart failure hospitalizations, slow CKD progression.

SPEAKER_00:

And provide modest weight loss. But safety requires careful counseling.

SPEAKER_01:

The genital mycotic infections.

SPEAKER_00:

Yes, from the glycoseria. And critically, they can cause euglycemic DKA.

SPEAKER_01:

Euglycemic DKA. So DKA without the sky high sugar, why does that happen?

SPEAKER_00:

Because the SGLT2s are making you excrete glucose, they can mask the hyperglycemia that usually warns us about DKA.

SPEAKER_01:

But the underlying catabolic state is still there.

SPEAKER_00:

The low insulin, high glucagon state is still present, driving ketone production and a life-threatening acidosis, even if the glucose is below 250.

SPEAKER_01:

And the other major class with weight loss and ASCVD risk reduction?

SPEAKER_00:

That would be the GLP1 receptor agonists, the saketides.

SPEAKER_01:

These are the incretin memetics.

SPEAKER_00:

Right. They stimulate glucose-dependent insulin secretion, slow gastric emptying, and have proven cardiovascular benefits.

SPEAKER_01:

And now we have the dual GIP GLP1 agonist, terzeptide.

SPEAKER_00:

Which offers even more potent glucose lowering and greater weight reduction.

SPEAKER_01:

But there's a key safety warning for the whole class.

SPEAKER_00:

A crucial one. A personal or family history of medullary thyroid cancer is an absolute contraindication.

SPEAKER_01:

And just to round out the toolkit, sulfanylurias and DPP4s?

SPEAKER_00:

Sulfonilureas work fast but have a very high risk of hypoglycemia and weight gain. DPP4 inhibitors are well tolerated, weight neutral, but generally less potent.

SPEAKER_01:

Which brings us to managing patients, clinical intervention, and health maintenance.

SPEAKER_00:

This is all about setting targets and preventing those devastating long-term complications. The general A1C target is below 7.0% for most non-pregnant adults. That's to reduce microvascular risk.

SPEAKER_01:

But and this is a big but that target is highly individualized. When do you relax it?

SPEAKER_00:

You have to relax it for certain populations. For frail or elderly patients or anyone with a history of severe hypoglycemia, you aim higher.

SPEAKER_01:

Less than 8.0%.

SPEAKER_00:

Often less than 8.0%. The immediate risk of a severe hypoglycemic event, a fall, a fracture, outweighs the long-term benefit of tight control in that patient.

SPEAKER_01:

And beyond glucose, we have to be aggressive about blood pressure and lipids.

SPEAKER_00:

Absolutely. BP target is typically less than 130 over 80, and statin therapy is standard for most T2DM patients between 40 and 75.

SPEAKER_01:

And the core of long-term health maintenance is just rigorous annual screening.

SPEAKER_00:

Three essential annual checks. Go. For nephropathy, you check the urine albumin to creatinine ratio, the UACR. A dilated eye exam.

SPEAKER_01:

And for neuropathy.

SPEAKER_00:

The annual foot exam we already discussed, using that Sims-Weinstein monofilament.

SPEAKER_01:

Okay, let's end with prevention and a few special situations. How powerful is T2DM prevention?

SPEAKER_00:

The data is just undeniable. The diabetes prevention program showed that lifestyle intervention.

SPEAKER_01:

So 7% weight loss and 150 minutes of weekly activity.

SPEAKER_00:

It reduces the incidence of T2DM by 58%. That's a better return on investment than almost any drug.

SPEAKER_01:

And for T1DM, there's actually a new preventative measure.

SPEAKER_00:

Yes, to plezemab. It's an anti-CD3 antibody.

SPEAKER_01:

And it can actually delay the onset.

SPEAKER_00:

It can delay symptomatic, stage three, T1DM, and high-risk individuals who are in that asymptomatic stage two. It buys them on average two to three years.

SPEAKER_01:

Finally, two quick rules for the hospital and for pregnancy.

SPEAKER_00:

In the hospital, you typically hold oral agents like metformin and SGLT2s. Insulin is preferred, usually a basal bolus regimen.

SPEAKER_01:

Not just a sliding scale.

SPEAKER_00:

Right. That's reactive, not proactive. Right. For pregnancy, strict glycemic targets are non-negotiable A1C below 6 to 6.5%, and insulin is the gold standard therapy.

SPEAKER_01:

Then what does this all mean? We've covered the spectrum. T1 DM is autoimmune absence. T2DM is resistance and failure.

SPEAKER_00:

And the diagnosis relies on hard numbers A1C over 6.5%, while treatment is tailored based on C peptide and the underlying pathology.

SPEAKER_01:

The essential takeaway is that diabetes management is a constant balancing act.

SPEAKER_00:

It's always about balancing long-term benefit against immediate risk.

SPEAKER_01:

Which brings us to our final thought. We talked about relaxing A1C targets for frail or elderly patients, moving from less than 7% to less than 8%. So here's the question for you, the clinician listener, to consider. If you have a 78-year-old patient, lives alone, has multiple comorbidities, how do you ethically and practically balance that long term benefit of tight control, which reduces microvascular damage years from now, against the immediate life threatening risk of severe hypoglycemia that could happen tonight if you're too aggressive?

SPEAKER_00:

That tension is at the very heart of individualized diabetes management. That's why this field is always evolving. Thank you for joining us.

SPEAKER_01:

We'll catch you on the next deep dive.